Business
Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies
NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that its President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci, and E. Antonio Chiocca, MD, PhD, FAANS, an investigator on Candel’s clinical trials in brain cancer, will present data and overviews pertaining to oncolytic viral immunotherapies for glioblastoma and other solid tumors at the following upcoming scientific conferences. Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit Conference Program: Oncolytic Virus ImmunotherapyDate and Time: Wednesday, Oct. 6, 2021Presenter: Paul Peter Tak, MD, PhD, FMedSciPresentation Title: Novel Oncolytic Viral Immunotherapies for Solid TumorsHanson Wade’s 6th Annual Oncolytic Virotherapy SummitDate and Time: Wednesday, Oct. 27, 2021Presenter: Paul Peter Tak, MD, PhD, FMedSciPresentation Title: Novel Oncolytic Viral Immunotherapies to Immunize Against the Patient’s Own Tumor Neo-antigens: CAN-2409 and CAN-3110 Hanson Wade’s 6th Annual Oncolytic Virotherapy SummitDate and Time: Wednesday, Oct. 27, 2021Presenter: E. Antonio Chiocca, MD, PhD, FAANSPresentation Title: Improving Oncolytic HSV1 for Glioblastoma Therapy Details from the presentations will be available on the Candel website at https://www.candeltx.com/news/. About CAN-2409 CAN-2409, Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the local release of tumor-specific neo-antigens. At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment. This creates the optimal conditions to induce a CD8+ T cell mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. Monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immun...